GLP-1 & Incretin Science
Normal Human Thyroid Has No Detectable GLP-1 Receptors
Waser and colleagues measured incretin receptors across rodent and human thyroid tissue. GLP-1 receptors are present in normal rat and mouse C-cells, and reach 100% incidence in rat C-cell hyperplasia and medullary thyroid carcinoma. No GLP-1 or GIP receptors were detected in normal human thyroid.
Key facts
- Study
- Waser 2011, Neuroendocrinology (PMID 21893952)
- Method
- In vitro receptor autoradiography
- Normal rodent C-cells
- GLP-1 receptors present
- Rat C-cell hyperplasia and MTC
- GLP-1R incidence 100%
- Normal human thyroid
- No GLP-1 or GIP receptors detected
- Human MTC, GLP-1R
- 27%
- Human MTC, GIP receptors
- Up to 89%, high density
Why receptor expression is the decisive question
The rodent effect was characterised as on-target — it proceeds through the GLP-1 receptor. An on-target effect requires the target. If human C-cells express the receptor at much lower density than rodent C-cells, the same drug would engage far less of the same pathway, and the rodent finding would not straightforwardly predict a human one.
What the measurements showed in rodents
GLP-1 receptors are expressed in C-cells of normal rat and mouse thyroid. Their density is markedly increased in rat C-cell hyperplasia and medullary thyroid carcinoma, where incidence reaches 100%. GIP receptors are absent from normal rodent thyroid and from C-cell hyperplasia, but present in all rat medullary thyroid carcinomas.
Research material referenced
Retatrutide 10mg — third-party HPLC tested
What they showed in humans
No GLP-1 or GIP receptors were detected in normal human thyroid at all. Among human medullary thyroid carcinomas, 27% expressed GLP-1 receptors while up to 89% expressed GIP receptors at high density. TT cells, a human medullary thyroid carcinoma line, lack GLP-1 receptors and express GIP receptors.
The asymmetry that is rarely stated
The boxed warning concerns GLP-1 receptor agonists and derives from rodent data. In human medullary thyroid carcinoma, the abundantly expressed incretin receptor is GIP at up to 89%, while GLP-1 is the rarer one at 27%. That is a receptor distribution observation, not evidence of harm from anything, and it does not appear in most discussion of this warning.
What this does and does not license concluding
It provides a mechanistic reason the rodent finding might not extend to humans — a reason grounded in measurement rather than assertion. It does not demonstrate safety. Receptor autoradiography describes what is present in tissue; whether an exposure produces an outcome over years is an epidemiological question, answered separately and by different methods.
Why the label wording is careful
Regulatory labelling states that it is unknown whether these agents cause thyroid C-cell tumours in humans, and that the human relevance of the rodent findings has not been determined. That is an accurate description of the position — a serious rodent signal, a species difference with a plausible mechanistic basis, and no resolution from the toxicology itself.
Quick reference
| Tissue | GLP-1 receptors | GIP receptors |
|---|---|---|
| Normal rat/mouse thyroid C-cells | Present | Not detected |
| Rat C-cell hyperplasia and MTC | 100% incidence | Present in all rat MTC |
| Normal human thyroid | Not detected | Not detected |
| Human medullary thyroid carcinoma | 27% | Up to 89%, high density |
Extended research context
The GLP-1 & Incretin Science deep dive
Deep dive: the two routes to a bigger effect
Every compound trying to beat GLP-1 alone has taken one of two routes. The first adds more receptors from the same hormone family — GIP in tirzepatide, GIP and glucagon in retatrutide. The second adds a non-incretin satiety hormone, which in practice means amylin: CagriSema combines cagrilintide with semaglutide, and amycretin engages both receptors from one molecule. Both routes work, because they recruit signalling pathways that do not fully overlap. Neither has escaped the constraint that binds all of them, which is that gastrointestinal tolerability worsens as effect size grows.
Deep dive: why a percentage is not a result
The most-quoted numbers in this field are the least comparable. REDEFINE 1 reported 22.7% and 20.4% for the same compound in the same trial — the first among participants who adhered to treatment, the second across everyone randomised. TRIUMPH-1 reported 28.3% in an uncomplicated obesity population while TRIUMPH-3 reported up to 22.6% in adults with established cardiovascular disease, using the same compound. Before any two figures can be compared they have to match on estimand, population, duration, comparator and whether the number is placebo-adjusted. Most published comparisons match on none of them.
Deep dive: what happens after the trial stops
Every headline figure describes weight while treatment continues. The STEP-1 extension found that a year after semaglutide was stopped, participants had given back roughly two-thirds of what they lost, moving from 17.3% mean reduction to a net 5.6% — though average weight remained below baseline and nearly half stayed at least 5% down. Meta-analysis puts regain at around 0.8 kg per month. This is why maintenance studies such as TRIUMPH-6 matter more to the field's future than another two points of peak reduction.
Research applications
- ▸Comparing incretin and amylin compounds on a like-for-like basis
- ▸Interpreting estimands, thresholds and placebo-adjusted figures in trial reports
- ▸Tracking the obesity pipeline across sponsors and jurisdictions
- ▸Understanding receptor pharmacology behind GLP-1, GIP, glucagon and amylin
- ▸Distinguishing licensed medicines from investigational compounds
Handling checklist
- ✓Identify which estimand a quoted percentage comes from before citing it
- ✓Check the trial population and baseline BMI against the comparison you are making
- ✓Confirm the duration and whether the reduction curve had plateaued
- ✓Read discontinuation rates alongside efficacy figures
- ✓Verify every NCT identifier against ClinicalTrials.gov rather than secondary reporting
Common research-handling mistakes
Learnt from thousands of researcher orders across our UK labs.
✗ Comparing headline percentages across different trials
Fix: Population, duration, estimand and comparator all differ; the numbers are not interchangeable.
✗ Quoting the larger of two figures from the same trial
Fix: Name the estimand. Efficacy and treatment-policy answer different questions.
✗ Treating peak reduction as a durable outcome
Fix: Substantial regain follows cessation across the class; peak figures describe a maintained state.
✗ Assuming an oral route means a weaker mechanism
Fix: Route and receptor count are independent. Orforglipron is weaker because it hits one receptor, not because it is a tablet.
✗ Reading investigational compounds as available treatments
Fix: Most of this pipeline holds no authorisation anywhere; mazdutide is approved only in China.
Continue researching
Peer-reviewed guides, comparators and matched reference materials.
Related questions researchers ask
- Which weight-loss compound produces the largest reduction?
- What is the difference between CagriSema and amycretin?
- What is an amylin receptor agonist?
- How much weight is regained after stopping a GLP-1?
- Why does CagriSema report two different percentages?
- Why is orforglipron less effective than retatrutide?
Frequently asked questions
- Do human thyroids have GLP-1 receptors?
- Waser 2011 detected no GLP-1 or GIP receptors in normal human thyroid, in contrast to normal rat and mouse C-cells where GLP-1 receptors are present.
- Does that mean the drugs are safe for the thyroid?
- No. It gives a mechanistic reason the rodent finding may not extend to humans. Whether an exposure produces an outcome is an epidemiological question answered by different methods.
- Which incretin receptor is common in human MTC?
- GIP, at up to 89% with high density. GLP-1 receptors appear in only 27% — the reverse of what the warning's framing suggests.
Primary sources & clinical trials
Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.
- PubMedWaser B et al., Incretin receptors in non-neoplastic and neoplastic thyroid C cells in rodents and humans: relevance for incretin-based diabetes therapy — Neuroendocrinology 2011 (PMID 21893952)pubmed.ncbi.nlm.nih.gov
- PubMedBjerre Knudsen L et al. — Endocrinology 2010 (PMID 20203154)pubmed.ncbi.nlm.nih.gov
- PubMedRosol TJ, On-target effects of GLP-1 receptor agonists on thyroid C-cells — Toxicol Pathol 2013 (PMID 23471186)pubmed.ncbi.nlm.nih.gov
- TrialClinicalTrials.gov · TRIUMPH-1 (NCT05929066) — Retatrutide pivotal obesity trialclinicaltrials.gov
- TrialClinicalTrials.gov · TRIUMPH-6 (NCT06859268) — Maintenance of weight reductionclinicaltrials.gov
- RefNovo Nordisk · CagriSema REDEFINE 1, published in NEJMprnewswire.com
- PubMedAmycretin phase 1b/2a subcutaneous study — PubMed (PMID 40550231)pubmed.ncbi.nlm.nih.gov
- RefTrajectory of weight regain after GLP-1 cessation — eClinicalMedicinethelancet.com
- PubMedOrforglipron: A Comprehensive Review — Int J Mol Sci 2026 (PMID 41683830)pubmed.ncbi.nlm.nih.gov
- EMAICH E9(R1) — estimands in clinical trials (EMA)ema.europa.eu
- GuidelineGoogle — Creating helpful, reliable, people-first contentdevelopers.google.com
Written and reviewed by
Jack Muncaster · Founder, UK Peptides
Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.
More GLP-1 & Incretin Science articles
- The Strongest Warning a Label CarriesA boxed warning is the most serious labelling a regulator applies. It does not mean a risk is proven — it means the consequence would be severe.
- The Hormone That Empties the Gallbladder, SuppressedCholecystokinin makes the gallbladder contract. GLP-1 suppresses cholecystokinin secretion — which is the identified mechanism behind the biliary events.
- What the Meta-Analysis EstablishedHe 2022 pooled randomised trials on gallbladder and biliary disease with GLP-1 receptor agonists. Why pooling was necessary for an outcome this infrequent.
- The Gallbladder Case Is Unusually CompleteObservation, then mechanism, then quantification. Most safety signals never get all three — which is why this one is worth studying as a template.
- What Happens to Bone When Load Comes OffBone responds to mechanical loading, so losing mass reduces the stimulus that maintains it. A 2025 critical appraisal examines what the medications add.
Popular across the research hub
One flagship guide from every other research category — keep exploring.
- Retatrutide ResearchRetatrutide Molecular Structure and Properties
- GHK-Cu (Copper Peptide)GHK-Cu Mechanism: What Is Actually Proposed
- TB-500 (Thymosin β4 fragment)How Actin Sequestration Works
- BPC-157 (Pentadecapeptide)BPC-157 Structure and Sequence
- CJC-1295 & IpamorelinIpamorelin Sequence and Chemical Identity
- Peptide ReferenceThe Method That Measures Peptide Directly
- Bacteriostatic WaterBenzyl Alcohol Chemical Identity
- Research & Regulatory NewsRetatrutide Expanded Access: What It Actually Is
- MOTS-c (Mitochondrial Peptide)MOTS-c Nuclear Translocation Under Metabolic Stress
- Semax (ACTH Fragment Peptide)Semax Mechanism: Neurotrophin Expression
- Selank (Tuftsin Analogue)Selank and BDNF: What the Studies Measured
- DSIP (Delta Sleep-Inducing Peptide)What the Field Said After Its First Decade
- KLOW (Blend)Four Identities, Four Masses, One Vial
- GLOW (Blend)One Volume, Three Peptides
- MT-2 (Melanotan II)The Receptor That Decides Which Pigment Is Made
- IGF-1 LR3Two Receptors Close Enough to Form Hybrids
- GlutathioneFour Jobs, Only One of Which the Label Describes
- NAD+The Clock Controls NAD, and NAD Feeds Back on the Clock
- KPVFragment Logic: KPV Against Its Parent